Released May 9, 2024, after the close
10-Q filed May 10, 2024, 40 days after period end · 0001636422-24-000075
Q1 2024 · 10-Q
Revenue$74.72M$74.72M +1.2% vs Q1 2023−0.5% vs Q4 2023
Net Income-$20.59M-$20.59M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.35-$0.35 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$22,812,000N/M
Operating Cash Flow$10,266,000N/M
Free Cash Flowderived$10,058,000N/M
Margins · derived
Operating margin-30.5%+16.7 pt vs Q1 2023
Net margin-27.6%+17.4 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $74.72M | $73.87M | $68.09M | $55.85M |
| Net Income | -$20.59M | -$33.19M | -$22.46M | -$28.37M |
| EPS Diluted | -$0.35 | -$0.60 | -$0.54 | -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR